Repository logo
 

Lessons from a randomised clinical trial for multidrug-resistant tuberculosis.

Simple item page
dc.contributor.authorPadayatchi, Nesri.
dc.contributor.authorMacKenzie, William R.
dc.contributor.authorHirsch-Moverman, Yael.
dc.contributor.authorFeng, P-J.
dc.contributor.authorVillarino, E.
dc.contributor.authorSaukkonen, J.
dc.contributor.authorHeilig, Charles M.
dc.contributor.authorWeiner, Marc.
dc.contributor.authorEl-Sadr, Wafaa M.
dc.date.accessioned2013-07-04T05:57:36Z
dc.date.available2013-07-04T05:57:36Z
dc.date.created2012
dc.date.issued2012
dc.description.abstractBACKGROUND: The treatment of multidrug-resistant tuberculosis (MDR-TB) is currently based upon expert opinion and findings from case series, rather than upon randomised clinical trials (RCTs). OBJECTIVE: To describe the challenges encountered during an RCT for the treatment of MDR-TB. METHODS: Tuberculosis Trials Consortium Study 30 was a pilot, Phase I/II, double-blind, placebo-controlled, RCT of the safety and tolerability of 16 weeks of daily, low-dose linezolid treatment for MDR-TB. RESULTS: A total of 36 patients, 56% of the target of 64 patients, consented to participate, for an average of 0.69 enrolments per week. Of the 36 patients enrolled, only 25 (69%) completed at least 90 doses of study treatment. Among the 12 (33%) patients who did not complete all 112 doses of the study treatment, the median time to study withdrawal was 15 days (range 0-92). After the study, we discovered discordance between treatment assignment and study drug for at least 9 (25%) of the 36 patients. CONCLUSIONS: Recruitment and retention in this MDR-TB clinical trial posed substantial challenges, suggesting the need for a large, multidisciplinary group of study staff to support the participants. Withdrawal tended to occur early in study treatment. The discrepancy in assigned study medication reflects the need for stronger administrative controls for study drugs.en
dc.identifier.citationPadayatchi, N. et al. 2012. Lessons from a randomised clinical trial for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis.16 (12) pp. 1582-1587.en
dc.identifier.issn1027-3719
dc.identifier.urihttp://dx.doi.org/10.5588/ijtld.12.0315.en
dc.identifier.urihttp://hdl.handle.net/10413/9245
dc.language.isoenen
dc.publisherInternational Union against Tuberculosis and Lung Disease.en
dc.subjectMultidrug-resistant tuberculosis--Treatment.en
dc.subjectClinical trials--Evaluation.en
dc.subjectHIV infections--Complications.en
dc.subject.otherMDR-TB.en
dc.subject.otherTuberculosis Trials Consortium (TBTC) Study 30.en
dc.titleLessons from a randomised clinical trial for multidrug-resistant tuberculosis.en
dc.typePeer reviewed journal articleen

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Padayatchi_Nesri_2012.pdf
Size:
519.71 KB
Format:
Adobe Portable Document Format
Description:
Journal article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.64 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Research papers (Caprisa)